Abstract:Abstract Breast cancer is the most common cancer among women. Of all breast cancers cases, approximately 30% have amplifications of the self-antigen HER2/neu. Later studies have also found antibody response and T cell response specific for HER2/neu in cancer patients, indicating HER2/neu may be a good target for active immunotherapy. Following studies on HER2/neu targeted immunotherapeutic strategies all have been proven to be incapable of breaking tolerance towards HER2/neu, and couldn't elicit adequate antitumor immunity in curing HER2/neu positive breast cancer in spontaneously developed tumor transgenic mouse model, although both humeral and cellular immune responses could be detected. CD4+ T helper cells play an essential role in antitumor immunity. Reports have demonstrated that CD8+ T cells at resting or non-responsive state can be activated by providing cytokines and co-stimulatory signals, suggesting T cell help activation is crucial in breaking CD8+ CTL tolerance. The tetanus toxoid Th P30 has been found to be a universal and potent epitope in sensitizing and proliferating CD4+ T cells ex vivo. In this study, to evaluate the P30 effect on vaccine efficacy, we constructed two recombinant AdVs (AdVOVA-P30 and AdVHER2/neu-P30) expressing ovalbumin (OVA)-P30 and HER2/neu-P30, and two AdV transduced DC vaccines (DCOVA-P30 and DCHER2/neu-P30), and then compared the the immunization efficacy between vaccines with and without Th epitope P30 in the same vaccine modality in wild-type C57BL6 mouse model, a mouse model for OVA/OVA-P30 system study, and FVNneuN mouse model, a in vivo murine tumor model expressing the rat neu Ag. We demonstrate that both AdVOVA and AdVOVA-P30 vaccines could stimulate super high level of OVA-specific CD8+ T lymphocytes (CTLs) in wild-type C56BL/6 mice, but with no significant defference. However, when assess the immune responses induced by DCOVA and DCOVA-P30, we found both of CD4+ T cell and OVA-sepcific CD8+ T cell responses induced by DCOVA-P30 are significantly higher than that of DCOVA. Futher study on in vivo cytotoxic assay also confirmed this finding. Althogh both of DCOVA and DCOVA-P30 vaccines could lead to preventive long-term immunity against OVA-expressing BL6-10OVA melanoma in metastasizing in wild-type C56BL/6 mice, therapeutic antitumor immunity induced by DCOVA-P30 vaccine could kill significantly higher amount of pre-existing BL6-10OVA melanoma, suggesting that with the help of the universal potent Th epitope P30, vaccine efficacy could be enhanced. When apply such vaccine modality to HER2/neu-tolerance mouse model FVNneuN so as to enhace the anti-HER2/neu immunity, we also found DCneu-P30 could stimulate stronger CD8+ T cell response that of DCHER2/neu, leading to signigicantly stronger preventive antitumor immunity against HER2/neu expressing tumor cell line from FVNneuN, prolonging the life span of FVNneuN mice. Citation Format: Yuxiu Chen, Yufeng Xie, Jim Xiang. Potent Th cell epitope modified HER2/neu dendritc cell vaccine magnify antitumor responses in HER2/neu tolerance transgenic mice. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; Dec 2-5, 2012; Miami, FL. Philadelphia (PA): AACR; Cancer Res 2013;73(1 Suppl):Abstract nr A26.

[Immunostimulatory effect of human peripheral blood dendritic cells transfected by adeno-associated virus containing Her2/neu gene].

Immunostimulatory activities of dendritic cells loaded with adenovirus vector carrying HBcAg/HBsAg.

HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination

Adjuvant Effect of HER-2/neu-specific Adenoviral Vector Stimulating CD8⁺ T and Natural Killer Cell Responses on Anti-Her-2/neu Antibody Therapy for Well-Established Breast Tumors in HER-2/neu Transgenic Mice.

Enhancement of non-MHC restricted anti-tumor effect of immunocytes by dendritic cells

A Single Low Dose of Dendritic Cells Modified with Lentivirus Containing a Truncated Neu Gene Can Effectively Suppress Neu-Overexpressing Tumors.

Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses

Anti-tumor effect of dendritic cell vaccines transfected with total RNA of A549 cells in vitro

The effect of IFNγ gene modified dendritic cells on T cell proliferation and eradication of tumor cells

[Dendritic Cells Infected by Recombinant Adeno-Associated Virus with CEA Gene to Induce Antigen-Specific CTL Response to CD44(+)CD24(-/low) Cells from MCF-7 Breast Cancer Cell Line].

Influence on Biological Characteristics of Dendritic Cells by Transfecting B7-H1 Antisense Gene

In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus.

Alpha-fetoprotein and IL-18 Gene-Modified Dendritic Cells-Induced CTL Response Against Hepatocellular Carcinoma Cells

[Dendritic Cells Elicit Cellular Immune Response by Targeting to Capture Breast Cancer Cells].

The Change and Clinical Significance of Recombinant Adenovirus Mediated Mouse HPSMA and 4-1BBL Gene Transfection of Dendritic Cells

Recombinant adenovirus-mediated survivin gene transfection of dendritic cells induces immune responses against renal cell carcinoma

Co-transfection Gene Delivery of Dendritic Cells Induced Effective Lymph Node Targeting and Anti-tumor Vaccination

Abstract A26: Potent Th Cell Epitope Modified HER2/neu Dendritc Cell Vaccine Magnify Antitumor Responses in HER2/neu Tolerance Transgenic Mice.

[Anti-Tumor Immune Response of Dendritic Cells Derived from Lymphoma Cells Transduced with Recombinant Adenovirus Encoding Human P53].

In Vitro Anti-Tumor Immune Response Induced by Dendritic Cells Transfected with Recombinant Adenovirus Carrying Mutant K-Ras Genes

The Direct Cytotoxic Effect of Dendritic Cells from Human Peripheral Blood and Cord Blood Upon the Cervical Carcinoma Cells Lines